CSF3 and acute myeloid leukemia: Starting from 2019, given the progressive increase in the number of patients with AML referred to our center, in the attempt to reduce hospitalization and allow more efficient inpatient flow management, we began routine administration of G-CSF (Filgrastim) as primary prophylaxis for febrile neutropenia (FN).